Biotechnology company Imugene (ASX:IMU) said a bile tract cancer patient in its phase 1 metastatic advanced solid tumors trial for Vaxinia, a treatment candidate for bile tract cancer, remained in complete response, surpassing over two years in remission, according to a Tuesday filing with the Australian bourse.
Meanwhile, the trial's bile tract cancer expansion phase cleared its first group, with the three patients experiencing no dose-limiting toxicities, and is now open for enrollment of up to 10 patients, the filing said.
The company also secured a patent extension to 2040 from the US Patent and Trademark Office for patent application number 16/324,541, protecting its oncolytic virotherapy CF33, including Vaxinia and CHECKVacc, according to the filing.
Imugene shares fell past 2% in morning trade Wednesday.
Price (AUD): $0.05, Change: $-0.001, Percent Change: -2.13%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。